Evaxion Unveils Promising Data for Personalized Cancer Vaccine EVX-01
Evaxion to Showcase Innovative Cancer Vaccine Data
Evaxion A/S (NASDAQ: EVAX) is set to present exciting new biomarker and immune data related to its flagship product, EVX-01, at the upcoming Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting. This annual event, known for showcasing the latest advancements in cancer treatment, will be held in National Harbor, highlighting innovations that can potentially transform patient outcomes.
Key Data Presentation on EVX-01
At this prestigious meeting, Evaxion will provide insights from its ongoing phase 2 trial of EVX-01, a personalized cancer vaccine aimed specifically at advanced melanoma treatment. Notably, this vaccine has been developed using Evaxion's proprietary AI-Immunology™ technology, which tailors treatments uniquely to the individual genetics and immune responses of patients.
Details of the SITC Presentation
This presentation will reveal new biomarker data that strengthens EVX-01’s already impressive profile, which includes supportive findings from previous clinical phases. A concise overview of the SITC presentation includes:
- Abstract title: Immune correlates of clinical response following treatment with the personalized cancer vaccine EVX-01 and Pembrolizumab in advanced melanoma patients
- Abstract #: 605
- Poster #: 605
- Session Category: Clinical trials in progress (Subcategory: Skin cancers)
- Location: Lower Level Atrium - Prince George's ABC
- Date/Time: Friday, November 7, 2025, 5:10–6:35 p.m. ET
- Presenter: Michail Angelos Pavlidis, Research Associate
Understanding EVX-01
EVX-01 represents the forefront of vaccine technology, specifically tailored for patients with advanced solid tumors. This personalized peptide-based vaccine utilizes advanced algorithms to analyze tumor markers unique to each patient, effectively guiding the immune response to target cancer cells.
Clinical results have been compelling, with EVX-01 achieving an impressive 69% overall response rate in patients with advanced melanoma. The predictive success of the AI-Immunology™ platform offers a glimpse into the future of personalized medicine, where treatments are not just generalized but crafted for the distinct needs of the patient.
Future Presentations on EVX-01
Continuing the momentum from the SITC meeting, Evaxion is also expected to share two-year clinical efficacy data at the European Society for Medical Oncology (ESMO) 2025 congress. This impending presentation is anticipated to further substantiate the robustness of EVX-01’s clinical profile.
About Evaxion and Its Vision
Evaxion is a pioneering entity in the TechBio sector, dedicated to innovating robust solutions in vaccine development fueled by artificial intelligence. Its AI-Immunology™ technology provides a cutting-edge approach to understanding the human immune system and designing effective treatments for various conditions such as cancers and infectious diseases.
Through ongoing development, Evaxion is committed to enhancing the therapeutic landscape, aiming to offer patients not just hope, but concrete solutions that are personalized and effective against their conditions. Evaxion's vision is about transforming lives and offering transformative treatment pathways, which are becoming a reality through advancements in AI and immunotherapy.
Contact Information
For more details, Evaxion A/S can be reached at:
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96
Email: mak@evaxion.ai
Frequently Asked Questions
What is EVX-01?
EVX-01 is a personalized peptide-based cancer vaccine developed by Evaxion, aimed at treating advanced melanoma.
When will the SITC presentation occur?
The SITC presentation is scheduled for November 7, 2025, from 5:10 to 6:35 p.m. ET.
What are the clinical trial results for EVX-01?
EVX-01 has demonstrated promising overall response rates of 69% in advanced melanoma patients during clinical trials.
How does AI-Immunology™ benefit treatment?
AI-Immunology™ tailors vaccine design to each patient's unique tumor profile, enhancing the immune response against cancer cells.
Who should be contacted for more information about Evaxion?
Mads Kronborg, the Vice President of Investor Relations & Communication at Evaxion, is the contact person for inquiries.
About The Author
Contact Ryan Hughes privately here. Or send an email with ATTN: Ryan Hughes as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
